Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis

Journal of Cellular and Molecular Medicine - Tập 12 Số 5a - Trang 1527-1534 - 2008
Michael V. Grandal1,2, Inger Helene Madshus2
1University of Copenhagen, Department of Cellular and Molecular Medicine, The Panum Building, Copenhagen, Denmark
2University of Oslo, Institute of Pathology, Rikshospitalet, Oslo, Norway

Tóm tắt

Introduction

Endocytosis of EGFR

Cellular and molecular requirements for lysosomal degradation of EGFR

Abstract

The epidermal growth factor receptor (EGFR) and other members of the EGFR/ErbB receptor family of receptor tyrosine kinases (RTKs) are important regulators of proliferation, angiogenesis, migration, tumorigenesis and metastasis. Overexpression, mutations, deletions and production of autocrine ligands contribute to aberrant activation of the ErbB proteins. The signalling output from EGFR is complicated given that other ErbB proteins are often additionally expressed and activated in the same cell, resulting in formation of homo‐and/or heterodimers. In particular, association of EGFR with ErbB2 prevents its down‐regulation, underscoring the importance of the cellular background for EGFR effects. Signalling from ErbB proteins can either be terminated by dissociation of ligand resulting in dephosphorylation, or blunted by degradation of the receptors. Although proteasomal targeting of ErbB proteins has been described, lysosomal degradation upon ligand‐induced endocytosis seems to play the major role in EGFR down‐regulation. Preclinical and clinical data have demonstrated that EGFR is a central player in cancer, especially in carcinomas, some brain tumours and in non‐small cell lung cancer. Such studies have further validated EGFR as an important molecular target in cancer treatment. This review focuses on mechanisms involved in ligand‐induced EGFR activation and endocytic down‐regulation. A better understanding of EGFR biology should allow development of more tumour‐selective therapeutic approaches targeting EGFR‐induced signalling.

Từ khóa


Tài liệu tham khảo

10.1038/35052073

10.1093/emboj/19.13.3159

10.1677/erc.0.0080083

10.1016/S0959-8049(01)00230-1

10.1677/erc.1.00600

10.1073/pnas.72.4.1317

10.1016/S1097-2765(03)00047-9

10.1038/nrc1609

10.2165/00003495-200060001-00002

Hirata A, 2002, ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase, Cancer Res., 62, 2554

10.1074/jbc.271.9.5251

10.1083/jcb.200305145

10.1128/MCB.26.2.389-401.2006

10.1093/oxfordjournals.bmb.a072464

Reiss M, 1991, Activation of the autocrine transforming growth factor alpha pathway in human squamous carcinoma cells, Cancer Res., 51, 6254

10.1158/1078-0432.CCR-06-0555

10.1002/jcb.20554

10.1038/sj.onc.1209662

10.4161/cbt.5.10.3226

10.1093/carcin/bgm058

10.1083/jcb.117.1.203

10.1083/jcb.129.1.47

Wiley HS, 1991, The role of tyrosine kinase activity in endocytosis, compartmentation, and down‐regulation of the epidermal growth factor receptor, J Biol Chem., 66, 11083, 10.1016/S0021-9258(18)99131-3

10.1074/jbc.M201595200

10.1038/sj.embor.7400491

10.1091/mbc.e02-08-0532

10.1111/j.1600-0854.2006.00420.x

10.1038/sj.emboj.7601297

10.1111/j.1600-0854.2006.00487.x

10.1074/jbc.C400046200

10.1083/jcb.95.1.73

10.1016/0092-8674(84)90006-0

10.1073/pnas.0409817102

10.1074/jbc.274.43.30636

10.1242/jcs.115.6.1331

10.1111/j.1749-6632.2001.tb05638.x

10.1242/jcs.03167

10.1158/0008-5472.CAN-06-3397

10.1038/ncb983

10.1093/emboj/21.3.303

10.1016/j.molcel.2006.02.018

Galcheva‐Gargova Z, 1995, The epidermal growth factor receptor is covalently linked to ubiquitin, Oncogene., 11, 2649

10.1158/0008-5472.CAN-06-1042

10.1034/j.1600-0854.2003.t01-1-00109.x

10.1073/pnas.0707416104

10.1074/jbc.271.46.28727

10.1091/mbc.e04-01-0041

Polo S, 2003, EH and UIM: endocytosis and more, Sci STKE., 213, 1

10.1016/S0092-8674(00)80791-6

10.1073/pnas.96.16.8907

10.1074/jbc.274.22.15671

10.1074/jbc.274.48.33959

10.1074/jbc.M104226200

10.1111/j.1600-0854.2006.00383.x

10.1159/000055396

10.1126/science.3798106

10.1091/mbc.E03-08-0596

10.1091/mbc.E05-05-0456

10.2174/156800906778742479

10.1021/jm980403y

10.1074/jbc.M006864200

10.1097/00001622-200311000-00003

10.1016/S1535-6108(03)00029-1

10.1091/mbc.10.5.1621

10.1081/RRS-120014607

10.1016/S1535-6108(04)00083-2

10.1111/j.1349-7006.2007.00553.x

10.1016/j.tcb.2006.08.004

10.1038/28879

10.1016/S0955-0674(03)00080-2

10.1034/j.1600-0854.2001.20905.x

10.1093/emboj/20.18.5176

10.1038/ncb791

10.1091/mbc.E07-07-0678

10.1158/0008-5472.CAN-07-0484